Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dld.2021.11.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The need of HVPG-guided beta-blocker therapy for NASH cirrhosis with varices - Answer is still up in the air.
Dig Liver Dis
May 2022
Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai, India. Electronic address:
The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
Dig Liver Dis
April 2022
Divison of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. Electronic address:
Background And Aims: Non-alcoholic steatohepatitis has become a leading cause of cirrhosis. The prognostic value of (HVPG)-guided NSBB prophylaxis remains to be investigated in the setting of NASH cirrhosis.
Methods: Patients with NASH cirrhosis and varices undergoing HVPG-guided NSBB therapy were included.
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
Aliment Pharmacol Ther
April 2018
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Background: Sequential measurements of hepatic venous pressure gradient (HVPG) are used to assess the haemodynamic response to nonselective betablockers (NSBBs) in patients with portal hypertension.
Aims: To assess the rates of HVPG response to different doses of carvedilol.
Methods: Consecutive patients with cirrhosis undergoing HVPG-guided carvedilol therapy for primary prophylaxis of variceal bleeding between 08/2010 and 05/2015 were retrospectively included.
A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
Hepatology
May 2017
Gastrointestinal Bleeding Unit, Department of Gastroenterology, Hospital de Sant Pau, Barcelona, Autonomous University, Barcelona, Spain.
Unlabelled: Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB. Patients with cirrhosis with controlled variceal bleeding were randomized to an HVPG-guided therapy group (N = 84) or to a control group (N = 86).
View Article and Find Full Text PDFHepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis.
Int J Clin Exp Med
January 2016
Department of Gastroenterology and Hepatology, Shandong Provincial Hospital Affilliated to Shandong Univercity Jinan, People's Republic of China.
Background: The best therapy to prevent esophageal variceal (EV) rebleeding in cirrhotic patients who are non-responsive to pharmacological therapy have not been determined.
Aims: To evaluate efficacy of a strategy to assign different treatments according to hepatic vein pressure gradient (HVPG) values to prevent EV rebleeding in non-responders.
Methods: This study is a non-randomized controlled prospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!